Aktis Oncology Surges in Their Nasdaq Debut

Aktis Oncology (NASDAQ: AKTS) shares surged roughly 50% on Friday after the cancer-focused biotechnology company made its debut on the Nasdaq Global Market, opening at $27 per share compared with its $18 IPO price.

Aktis Oncology priced its initial public offering at the top end of its marketed range and expanded the deal size ahead of listing. The company sold 17.65 million shares, up from an earlier plan to offer 11.8 million shares, reflecting strong investor demand. The IPO values the company as it advances a pipeline centered on targeted radiopharmaceutical therapies for oncology indications.

Institutional interest was highlighted by a significant commitment from Eli Lilly & Co., which agreed to purchase approximately $100 million worth of shares, according to regulatory filings. The offering was led by a syndicate of major underwriters, with an overallotment option for up to an additional 2.65 million shares.

Aktis Oncology is focused on developing radiopharmaceuticals designed to precisely target cancer cells. Its lead candidate, [225Ac]Ac-AKY-1189, is engineered to target Nectin-4, a protein expressed on several tumor types with limited presence in normal adult tissues. The company initiated a multi-site Phase 1b clinical trial in the U.S. after receiving FDA clearance for its investigational new drug application in April 2025, with initial data expected in the first quarter of 2027.

The company is backed by life sciences investors including MPM BioImpact and Vida Ventures and qualifies as both an emerging growth company and a smaller reporting company, allowing for reduced regulatory reporting requirements during its early years as a public company.

Key takeaways and significance

• Strong Nasdaq debut underscores investor appetite for oncology-focused biotech IPOs.

• Upsized offering and top-of-range pricing signal robust institutional demand.

• Strategic investment interest from a major pharmaceutical company enhances credibility.

• Lead radiopharmaceutical candidate targets a well-validated oncology marker (Nectin-4).

• Upcoming Phase 1b clinical data represents a major potential catalyst for the stock.